Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Alessandro Rizzo, Vincenzo Dadduzio, Angela Dalia Ricci, Francesco Massari, Alessandro Di Federico, Gennaro Gadaleta-Caldarola & Giovanni Brandi. (2022) Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. Expert Opinion on Investigational Drugs 31:4, pages 371-378.
Read now
Read now
Laura Kulik, Leonardo G da Fonseca, Aiwu Ruth He, Jordi Rimola, Andrea Wilson Woods, York F Zöllner & Peter R Galle. (2020) Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion. Journal of Hepatocellular Carcinoma 7, pages 423-433.
Read now
Read now
Tong Liu, Sainan Li, Liwei Wu, Qiang Yu, Jingjing Li, Jiao Feng, Jie Zhang, Jiaojiao Chen, Yuting Zhou, Jie Ji, Kan Chen, Yuqing Mao, Fan Wang, Weiqi Dai, Xiaoming Fan, Jianye Wu & Chuanyong Guo. (2020) Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2. Journal of Hepatocellular Carcinoma 7, pages 19-31.
Read now
Read now
Articles from other publishers (43)
Gopika Chandrababu, Sunil Kumar Sah, Ayana R. Kumar, Sabitha M & Lekshmi R. Nath. (2023) Green Synthesized Nanoparticles as a Plausible Therapeutic Strategy
Against Hepatocellular Carcinoma: An Update on its Preclinical and
Clinical Relevance. Recent Patents on Anti-Cancer Drug Discovery 18:3, pages 268-291.
Crossref
Crossref
Da Zhang, Chenwei Jiang, Xiaoyuan Zheng, Zhiwen Lin, Qiuyu Zhuang, Huanzhang Xie, Yuzhi Liang, Yu Xu, Linsheng Cui, Xiaolong Liu & Yongyi Zeng. (2023) Normalization of Tumor Vessels by Lenvatinib‐Based Metallo‐Nanodrugs Alleviates Hypoxia and Enhances Calreticulin‐Mediated Immune Responses in Orthotopic HCC and Organoids. Small.
Crossref
Crossref
Jianpeng Sheng, Jiangchao Wu, Xianghong Yin, Zhu Sun, Xun Wang, Junlei Zhang, Jianghui Tang, Yongtao Ji, Jinyuan Song, Xiaobao Wei, Lin Wang, Yaxing Zhao, Hui Zhang, Taohong Li, Qi Zhang, Xueli Bai, Li Chen, Dong Chen & Tingbo Liang. (2023) Synergetic treatment of oxygen microcapsules and lenvatinib for enhanced therapy of HCC by alleviating hypoxia condition and activating anti-tumor immunity. Chinese Chemical Letters 34:4, pages 107738.
Crossref
Crossref
Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang & Seung Up Kim. (2022) Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology 35:2, pages 191-197.
Crossref
Crossref
David Jeremie Birnbaum, Maelle Picard, Quentin Da Costa, Thomas Delayre, Pascal Finetti, Olivier Cabaud, Emilie Agavnian, Bernadette De Rauglaudre, Emilie Denicolaï, François Bertucci & Emilie Mamessier. (2023) PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma. Cancers 15:2, pages 447.
Crossref
Crossref
Xin Han, Jianhua Wu, Ziyue Sha, Ruixue Lai, Jianfei Shi, Lili Mi, Fei Yin & Zhanjun Guo. (2023) Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway. Clinical Medicine Insights: Oncology 17, pages 117955492311612.
Crossref
Crossref
Pramodkumar Pyarelal Gupta, Viraj Jitendra Sadrani, Priyanshu Pramodkumar Gupta, Mala Makarand Parab & Virupaksha Ajit Bastikar. 2023. Oncogenic Viruses. Oncogenic Viruses
243
262
.
Sidra Altaf, Faiza Saleem, Azam Ali Sher & Ashiq Ali. (2022) Potential Therapeutic Strategies to Combat HCC. Current Molecular Pharmacology 15:7, pages 929-942.
Crossref
Crossref
Ihtzaz Ahmed Malik, Mansi Rajput, Rieke Werner, Dorothea Fey, Niloofar Salehzadeh, Christine A. F. von Arnim & Jörg Wilting. (2022) Differential in vitro effects of targeted therapeutics in primary human liver cancer: importance for combined liver cancer. BMC Cancer 22:1.
Crossref
Crossref
Yuen Chak Tiu, Lanqi Gong, Yu Zhang, Jie Luo, Yuma Yang, Ying Tang, Wing-mui Lee & Xin-Yuan Guan. (2022) GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway. Cancer Gene Therapy 29:11, pages 1720-1730.
Crossref
Crossref
Priyadarshini Mohapatra & Natarajan Chandrasekaran. (2022) Wnt/β-catenin targeting in liver carcinoma through nanotechnology-based drug repurposing: A review. Biomedicine & Pharmacotherapy 155, pages 113713.
Crossref
Crossref
Xiaopei Hao, Yao Zhang, Xiaoli Shi, Hanyuan Liu, Zhiying Zheng, Guoyong Han, Dawei Rong, Chuanyong Zhang, Weiwei Tang & Xuehao Wang. (2022) CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Crossref
Sarah M. El-Demiry, Mohamed El-Yamany, Saad M. El-Gendy, H.A. Salem & Mona M. Saber. (2022) Necroptosis modulation by cisplatin and sunitinib in hepatocellular carcinoma cell line. Life Sciences 301, pages 120594.
Crossref
Crossref
Hiroki Tanaka, Kie Horioka, Takumu Hasebe, Koji Sawada, Shunsuke Nakajima, Hiroaki Konishi, Shotaro Isozaki, Masanori Goto, Yumiko Fujii, Yuki Kamikokura, Katsuhiro Ogawa & Yuji Nishikawa. (2021) Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor‐platelet interactions. International Journal of Cancer 150:10, pages 1640-1653.
Crossref
Crossref
Natasha Chandok, Sanjeev Sirpal & Eric M Yoshida. (2022)
Checkpoint inhibition in hepatocellular carcinoma: Outsmarting the
Squid Game
. Canadian Liver Journal 5:2, pages 165-168.
Crossref
Crossref
Darko Castven, Carolin Czauderna, Diana Becker, Sharon Pereira, Jennifer Schmitt, Arndt Weinmann, Viral Shah, Jovana Hajduk, Friederike Keggenhoff, Harald Binder, Tobias Keck, Stefanie Heilmann‐Heimbach, Marcus A. Wörns, Snorri S. Thorgeirsson, Kai Breuhahn, Peter R. Galle & Jens U. Marquardt. (2021) Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer Cells. Hepatology Communications 6:5, pages 1140-1156.
Crossref
Crossref
Pengfei Zhang, Haixiang Sun, Peihao Wen, Yilin Wang, Yuehong Cui & Jing Wu. (2022) circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. Molecular Therapy - Nucleic Acids 27, pages 293-303.
Crossref
Crossref
Shufeng Wang, Xinzheng Wang, Xin Yang, Feng Liu, Jin Li, Weihua Li, Zhaofang Bai, Hongbo Wang, Jie Mao, Tingting Li, Kun He & Hongxia Wang. (2022) Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues. PROTEOMICS 22:4, pages 2100141.
Crossref
Crossref
Aimen Farooq, Zohaib Ahmed, James Wert, Anum Jalil, James Yu, Vadim Zaytsev & Sarfraz Ahmad. 2022. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3
259
273
.
Haiwei Zhang, Juan Zhao, Wei Yang, Zheng Li, Li Gong & Yongsheng Li. 2022.
Abid Ali Khan, Zhi-Kun Liu & Xiao Xu. (2021) Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 20:6, pages 511-520.
Crossref
Crossref
Qingchun Lu, Qian Guo, Mingyang Xin, Casey Lim, Ana M. Gamero, Glenn S. Gerhard & Ling Yang. (2021) LncRNA TP53TG1 Promotes the Growth and Migration of Hepatocellular Carcinoma Cells via Activation of ERK Signaling. Non-Coding RNA 7:3, pages 52.
Crossref
Crossref
Mustafa Karabicici, Yagmur Azbazdar, Gunes Ozhan, Serif Senturk, Zeynep Firtina Karagonlar & Esra Erdal. (2021) Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Carol Lai-Hung Cheng, Felice Hoi-Ching Tsang, Lai Wei, Mengnuo Chen, Don Wai-Ching Chin, Jialing Shen, Cheuk-Ting Law, Derek Lee, Carmen Chak-Lui Wong, Irene Oi-Lin Ng & Chun-Ming Wong. (2021) Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer. Communications Biology 4:1.
Crossref
Crossref
Konstantinos Damiris, Hamza Abbad & Nikolaos Pyrsopoulos. (2021) Cellular based treatment modalities for unresectable hepatocellular carcinoma. World Journal of Clinical Oncology 12:5, pages 290-308.
Crossref
Crossref
Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim & Seung Up Kim. (2020) Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 36:5, pages 1317-1325.
Crossref
Crossref
Marina Galicia-Moreno, Jorge A Silva-Gomez, Silvia Lucano-Landeros, Arturo Santos, Hugo C Monroy-Ramirez & Juan Armendariz-Borunda. (2021) Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models. Canadian Journal of Gastroenterology and Hepatology 2021, pages 1-10.
Crossref
Crossref
Astha Malik, Unmesha Thanekar, Surya Amarachintha, Reena Mourya, Shreya Nalluri, Alexander Bondoc & Pranavkumar Shivakumar. (2021) “Complimenting the Complement”: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Frontiers in Oncology 10.
Crossref
Crossref
Takeshi Hatanaka, Atsushi Naganuma & Satoru Kakizaki. (2021) Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals 14:1, pages 36.
Crossref
Crossref
Arndt Vogel, Catherine Frenette, Max Sung, Bruno Daniele, Ari Baron, Stephen L. Chan, Jean Frédéric Blanc, Toshiyuki Tamai, Min Ren, Howard J. Lim, Daniel H. Palmer, Yuko Takami & Masatoshi Kudo. (2021) Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer 10:5, pages 510-521.
Crossref
Crossref
Jie Zhang, Qianqian Song, Mengna Wu & Wenjie Zheng. (2020) The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular Carcinoma. Current Medicinal Chemistry 28:1, pages 93-109.
Crossref
Crossref
Nia Adeniji & Renumathy Dhanasekaran. (2020) Genomic Landscape of HCC. Current Hepatology Reports 19:4, pages 448-461.
Crossref
Crossref
Chia-Chi Lin, Tsai-Sheng Yang, Chia-Jui Yen, Rebecca Cheng, Junjun Liu & Chiun Hsu. (2020) Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study. The Oncologist 25:12, pages e1921-e1929.
Crossref
Crossref
Michela Anna Polidoro, Joanna Mikulak, Valentina Cazzetta, Ana Lleo, Domenico Mavilio, Guido Torzilli & Matteo Donadon. (2020) Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World Journal of Gastroenterology 26:33, pages 4900-4918.
Crossref
Crossref
Ramesh P Thylur, Sanjit K Roy, Anju Shrivastava, Thomas A LaVeist, Sharmila Shankar & Rakesh K Srivastava. (2020) Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open 4:3, pages 351-359.
Crossref
Crossref
Patrick Stoiber, Iriny Ekladious, Qing Zhao, Yolonda L. Colson, Scott E. Schaus, Ulla Hansen & Mark W. Grinstaff. (2020) Expansile Nanoparticles Encapsulate Factor Quinolinone Inhibitor 1 and Accumulate in Murine Liver upon Intravenous Administration. Biomacromolecules 21:4, pages 1499-1506.
Crossref
Crossref
Meghan Bell, Evrim B. Turkbey & Freddy E. Escorcia. (2020) Radiomics, Radiogenomics, and Next-Generation Molecular Imaging to Augment Diagnosis of Hepatocellular Carcinoma. The Cancer Journal 26:2, pages 108-115.
Crossref
Crossref
Qinghai Lin, Zhuanchang Wu, Xuetian Yue, Xiangguo Yu, Zehua Wang, Xiaojia Song, Leiqi Xu, Ying He, Yutong Ge, Siyu Tan, Tixiao Wang, Hui Song, Detian Yuan, Yaoqin Gong, Lifen Gao, Xiaohong Liang & Chunhong Ma. (2020) ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation. EBioMedicine 53, pages 102676.
Crossref
Crossref
Chandramohan Kiruthiga, Kasi Pandima Devi, Seyed M. Nabavi & Anupam Bishayee. (2020) Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma. Cancers 12:3, pages 562.
Crossref
Crossref
Zhonglin Hao & Peng Wang. (2020) Lenvatinib in Management of Solid Tumors. The Oncologist 25:2, pages e302-e310.
Crossref
Crossref
Yanli Liu, Jiaye Zhang, Yan Chen, Hasan Sohel, Xinrong Ke, Jingqi Chen & Yin-Xiong Li. (2020) The correlation and role analysis of COL4A1 and COL4A2 in hepatocarcinogenesis. Aging 12:1, pages 204-223.
Crossref
Crossref
Saroja Bangaru, Jorge A. Marrero & Amit G. Singal. (2020) Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 51:1, pages 78-89.
Crossref
Crossref
Nakka Venkata Prasuja. 2020. Immunotherapy for Gastrointestinal Malignancies. Immunotherapy for Gastrointestinal Malignancies
51
60
.